BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. increased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 12.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 97,261 shares of the biotechnology company's stock after purchasing an additional 10,687 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.05% of BioMarin Pharmaceutical worth $6,875,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Wealthquest Corp acquired a new stake in shares of BioMarin Pharmaceutical during the first quarter worth $234,000. Lecap Asset Management Ltd. lifted its holdings in shares of BioMarin Pharmaceutical by 15.7% during the first quarter. Lecap Asset Management Ltd. now owns 9,822 shares of the biotechnology company's stock worth $694,000 after purchasing an additional 1,330 shares during the period. Asset Management One Co. Ltd. lifted its holdings in shares of BioMarin Pharmaceutical by 5.3% during the first quarter. Asset Management One Co. Ltd. now owns 80,879 shares of the biotechnology company's stock worth $5,717,000 after purchasing an additional 4,094 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in BioMarin Pharmaceutical in the first quarter valued at $383,000. Finally, Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in BioMarin Pharmaceutical in the first quarter valued at $388,000. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Stock Up 2.0%

NASDAQ BMRN opened at $55.17 on Monday. The stock has a market cap of $10.58 billion, a PE ratio of 20.51, a P/E/G ratio of 0.76 and a beta of 0.19. BioMarin Pharmaceutical Inc. has a fifty-two week low of $52.93 and a fifty-two week high of $94.85. The business has a 50 day moving average price of $58.39 and a two-hundred day moving average price of $63.21. The company has a quick ratio of 3.49, a current ratio of 5.52 and a debt-to-equity ratio of 0.10.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Citigroup reduced their target price on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. The Goldman Sachs Group reduced their target price on BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating for the company in a report on Monday, May 5th. Finally, Wall Street Zen raised BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, BioMarin Pharmaceutical currently has an average rating of "Moderate Buy" and an average target price of $93.45.

Insider Activity

In other news, CAO Erin Burkhart sold 1,786 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the transaction, the chief accounting officer now directly owns 14,173 shares in the company, valued at approximately $840,600.63. This represents a 11.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.85% of the company's stock.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.